AR104935A1 - Formas cristalinas de un inhibidor de histona deacetilasa - Google Patents

Formas cristalinas de un inhibidor de histona deacetilasa

Info

Publication number
AR104935A1
AR104935A1 ARP160101702A ARP160101702A AR104935A1 AR 104935 A1 AR104935 A1 AR 104935A1 AR P160101702 A ARP160101702 A AR P160101702A AR P160101702 A ARP160101702 A AR P160101702A AR 104935 A1 AR104935 A1 AR 104935A1
Authority
AR
Argentina
Prior art keywords
deacetilasa
histona
inhibitor
crystal forms
crystal
Prior art date
Application number
ARP160101702A
Other languages
English (en)
Spanish (es)
Inventor
Liu Gui
Seyedi Farzaneh
H Van Duzer John
Original Assignee
Acetylon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acetylon Pharmaceuticals Inc filed Critical Acetylon Pharmaceuticals Inc
Publication of AR104935A1 publication Critical patent/AR104935A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP160101702A 2015-06-08 2016-06-08 Formas cristalinas de un inhibidor de histona deacetilasa AR104935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172629P 2015-06-08 2015-06-08

Publications (1)

Publication Number Publication Date
AR104935A1 true AR104935A1 (es) 2017-08-23

Family

ID=56178492

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101702A AR104935A1 (es) 2015-06-08 2016-06-08 Formas cristalinas de un inhibidor de histona deacetilasa

Country Status (6)

Country Link
US (1) US10464906B2 (enExample)
EP (1) EP3303306B1 (enExample)
JP (1) JP6816036B2 (enExample)
AR (1) AR104935A1 (enExample)
TW (1) TW201718516A (enExample)
WO (1) WO2016200919A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1207403A1 (en) 2012-04-19 2016-01-29 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
TWI706937B (zh) 2015-06-08 2020-10-11 美商艾斯特隆製藥公司 製備蛋白質去乙醯酶抑制劑之方法
EP3468559B1 (en) * 2016-06-09 2023-11-22 Dana Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
JP7100018B2 (ja) 2016-08-08 2022-07-12 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用
EP3544600A4 (en) 2016-11-23 2020-06-17 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLAS INHIBITOR AND A PROGRAMMED DEATH LIGAND-1 (PD-L1) INHIBITOR AND METHOD FOR USE THEREOF

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
JP2003528074A (ja) 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
WO2002074298A1 (en) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
AU2002363174B2 (en) 2001-11-01 2008-09-25 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2561617A1 (en) 2004-04-05 2005-10-20 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
CA2620414A1 (en) 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
WO2008091349A1 (en) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
WO2007130429A2 (en) 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2007144341A1 (en) 2006-06-12 2007-12-21 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
WO2008033746A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
TWI478709B (zh) 2008-02-19 2015-04-01 Earnest Medicine Co Ltd A useful oral or enteral composition for the recovery of bodily functions
EP2321264B1 (en) 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
US8716326B2 (en) 2009-05-15 2014-05-06 Korea Research Institute Of Chemical Technology Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
WO2011084991A2 (en) 2010-01-08 2011-07-14 President And Fellows Of Harvard College Fluorinated hdac inhibitors and uses thereof
PL2526093T3 (pl) 2010-01-22 2017-02-28 Acetylon Pharmaceuticals, Inc. Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania
EP2571352A4 (en) 2010-05-21 2014-09-17 Sloan Kettering Inst Cancer SELECTIVE HDAC HEMMER
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
NZ610225A (en) 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2734500A4 (en) 2011-07-20 2015-04-08 Gen Hospital Corp SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
HK1207403A1 (en) 2012-04-19 2016-01-29 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
WO2014059306A1 (en) 2012-10-12 2014-04-17 The Trustees Of The University Of Pennsylvania Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
JP2016511237A (ja) 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 選択的ｈｄａｃ３阻害剤
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
US20140357512A1 (en) 2013-06-03 2014-12-04 Acetylon Pharmaceuticals, Inc. Histone deacetylase (hdac) biomarkers in multiple myeloma
JP2016531163A (ja) 2013-09-20 2016-10-06 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｈｄａｃ６阻害物質を用いた、異常なリンパ球の機能に起因する疾患の治療
WO2015054099A1 (en) 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
WO2015054197A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
EP3055299B1 (en) 2013-10-10 2021-01-06 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
PE20161342A1 (es) 2013-10-11 2016-12-31 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
EP3060217B1 (en) 2013-10-24 2022-06-08 Mayo Foundation for Medical Education and Research Treatment of polycystic diseases with an hdac6 inhibitor
EP3076973B1 (en) 2013-12-03 2020-04-29 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
US20150176076A1 (en) 2013-12-20 2015-06-25 Acetylon Pharmaceuticals, Inc. Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US20150359794A1 (en) 2014-06-13 2015-12-17 Buck Institute For Research On Aging Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
CN107205988A (zh) 2014-07-07 2017-09-26 埃斯泰隆制药公司 利用组蛋白脱乙酰酶抑制剂治疗白血病
US20160137630A1 (en) 2014-10-08 2016-05-19 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
CN107438436A (zh) 2014-12-05 2017-12-05 摩德纳和雷焦艾米利亚大学 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合
US20160158231A1 (en) 2014-12-05 2016-06-09 Vib Vzw Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
CA2970500C (en) 2014-12-12 2023-08-29 Acetylon Pharmaceuticals, Inc. Piperidine derivatives as hdac1/2 inhibitors
WO2016168647A1 (en) 2015-04-17 2016-10-20 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibotrs
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
TWI706937B (zh) 2015-06-08 2020-10-11 美商艾斯特隆製藥公司 製備蛋白質去乙醯酶抑制劑之方法

Also Published As

Publication number Publication date
JP6816036B2 (ja) 2021-01-20
EP3303306A1 (en) 2018-04-11
JP2018516946A (ja) 2018-06-28
EP3303306B1 (en) 2020-02-12
TW201718516A (zh) 2017-06-01
US20170001965A1 (en) 2017-01-05
US10464906B2 (en) 2019-11-05
WO2016200919A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
IL277778B (en) Bcl6 inhibitors
HRP20251388T1 (hr) Supstituirani 6-azabenzimidazolni spojevi kao hpk1 inhibitori
PL3638666T3 (pl) Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy amidów kwasu tetrahydro- i dihydrofuranokarboksylowego
DK3529241T3 (da) Pireridinderivater som inhibitorer af ubiquitin-specifik protease 7
IL287668A (en) Crystalline forms of a btk inhibitor
SI3713919T1 (sl) Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida
HRP20260102T1 (hr) Spojevi ciklopropil-amida kao dvostruki inhibitori lsd1/hdac
HUE064559T2 (hu) MAGL inhibitor kristályos formája
DK3746424T3 (da) Erbb/btk-inhibitorer
MA42606A (fr) Sels d'un inhibiteur de lsd1
EP3801500A4 (en) Inhibitors of sarm1
DK3261639T3 (da) Substituerede pyrazolforbindelser som serinproteaseinhibitorer
DK3833665T3 (da) Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
EA201791684A1 (ru) Селективные ингибиторы bace1
DK3833662T3 (da) Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2-
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
IL286218A (en) Solid state forms of ripretinib
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
IL282454A (en) Crystalline salts of a plasma kallikrein inhibitor
EP4003986A4 (en) Inhibitor compounds
IL287736A (en) Diamondoid compounds
PL3552017T3 (pl) Związki użyteczne jako inhibitory RIPK1
EP3705471A4 (en) DOUBLE-HEADED PROTEASE INHIBITOR
DK3826983T3 (da) Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere
EP3831942A4 (en) INHIBITOR OF TDP-43 AGGREGATION

Legal Events

Date Code Title Description
FB Suspension of granting procedure